Meeting slides
Suggested Readings

Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir.

Akinosoglou K, Schinas G, Gogos C. Viruses. 2022;14(11):2540.

Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19.

Bierle DM, Ganesh R, Wilker CG, et al. J Prim Care Community Health. 2021;12:21501327211019282.

Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19).

Boucau J, Uddin R, Marino C, et al. Clin Infect Dis. 2023;76(3)e526-e529.

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the United Kingdom randomised, controlled open-label, platform adaptive trial.

Butler C, Hobbs R, Gbinigie O, et al. Lancet. 2022. [Epub ahead of print]

Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with Covid-19.

Ganatra S, Dani SS, Ahmad J, et al. Clin Infect Dis. 2022. [Epub ahead of print]

Early remdesivir to prevent progression to severe Covid-19 in outpatients.

Gottlieb RL, Vaca CE, Paredes R, et al. N Engl J Med. 2022;386(4):305-315.

Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.

Hammond J, Leister-Tebbe H, Gardner A, et al. N Engl J Med. 2022;386(15):1397-1408.

At the heart of the matter: unmasking and addressing the toll of COVID-19 on diverse populations.

Haynes N, Cooper LA, Albert MA. Circulation. 2020;142(2):105-107.

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.

Imai M, Ito M, Kiso M, et al. N Engl J Med. 2023;388(1):89-91.

Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients.

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. N Engl J Med. 2022;386(6):509-520.

Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review.

Notarte KI, Catahay JA, Velasco JV, et al. EClinicalMedicine. 2022;53:101624.

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.

Wang Q, Iketani S, Li Z, et al. Cell. 2023;186(2)279-286.e8.

Incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir.

Wong GL, Yip TC, Lai MS, et al. JAMA Netw Open. 2022;5(12):e2245086.

Impact of metabolic syndrome on severity of COVID-19 illness.

Wu S, Zhou K, Misra-Hebert A, et al. Metab Syndr Relat Disord. 2022;20(4):191-198.

Nirmatrelvir and the risk of post-acute sequelae of COVID-19.

Xie Y, Choi T, Al-Aly Z. medRxiv. 2022:2022.2011.2003.22281783.

ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.

Yue C, Song W, Wang L, et al. Lancet Infect Dis. 2023;23(3):278-280.

Related activities
1.00 CME/CE

What’s New in the Management of COVID-19

Incorporating New Data and Updated Guidelines Into Daily Practice

Faculty: Leigh Lewis Speicher, MD, MPH
Release: 03/24/2023
Expiration: 03/24/2024
1.00 ACPE

What Pharmacists Need to Know About Treating COVID-19

Incorporating New Data and Guidelines Into Practice

Faculty: Maggie Zhao, PharmD, BCCCP
Release: 03/31/2023
Expiration: 03/31/2024